|
|
Volumn 379, Issue 9815, 2012, Pages 507-
|
|
FDA rejects novel diabetes drug over safety fears
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
DAPAGLIFLOZIN;
HEMOGLOBIN A1C;
BLADDER CANCER;
BREAST CANCER;
CELL DEATH;
DRUG APPROVAL;
DRUG INDUSTRY;
DRUG MECHANISM;
DRUG SAFETY;
FOOD AND DRUG ADMINISTRATION;
GLUCOSE ABSORPTION;
HEMATURIA;
HUMAN;
HYPOGLYCEMIA;
NON INSULIN DEPENDENT DIABETES MELLITUS;
NOTE;
OBESITY;
PRIORITY JOURNAL;
RISK BENEFIT ANALYSIS;
WEIGHT REDUCTION;
|
|
EID: 84856881292
PISSN: 01406736
EISSN: 1474547X
Source Type: Journal
DOI: 10.1016/S0140-6736(12)60216-5 Document Type: Note |
|
Times cited : (42)
|
|
References (0)
|
